Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures ongoing ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the ...

US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...

AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.

Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...

The NSE Nifty 50 ended 254.65 points or 1.15% higher at 22,337.30, while the BSE Sensex closed 740.30 points or 1.01% up at ...

More than 1000 patients have been recruited by Panthera Biopartners the UK’s largest SMO (Site Management Organisation) who recruit patients and runs clinical trials for the pharmaceutical industry.

Republican-led House votes to censure Democrat Al Green over protest of president’s speech - Texas Democrat repeatedly interrupted president’s speech to Congress on Tuesday before being escorted out b ...